ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. President and CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz will host a webcast and conference call to discuss the results.
According to ANI Pharmaceuticals, webcast and call access links will be posted on the “Events & Presentations” page in the Investors section of its website, and a replay will be available for up to one year.
Positive
- None.
Negative
- None.
News Market Reaction – ANIP
In the Jul 24 session, ANIP declined 1.12%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Q1 earnings report | Positive | -2.4% | Reported Q1 results, raised guidance, and authorized a share repurchase program. |
| Apr 24 | Q1 earnings scheduling | Neutral | +0.7% | Announced the May 8 release date and conference call for Q1 results. |
| Feb 27 | Q4 earnings report | Positive | -4.2% | Reported record Q4 and full-year results and reaffirmed 2026 guidance. |
| Feb 13 | Q4 earnings scheduling | Neutral | +0.9% | Announced the February 27 release date for fourth-quarter results. |
| Nov 07 | Q3 earnings report | Positive | +0.2% | Reported record Q3 results and raised full-year 2025 guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings events averaged a -0.97% 24-hour reaction, with reported results producing both positive and negative reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.
To view the webcast, please click here. Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com, under the “Investors” section. A replay of the event will remain accessible for up to one year.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.
Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com
Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com
SOURCE: ANI Pharmaceuticals, Inc.
